Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. 1973

S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman

UI MeSH Term Description Entries
D008297 Male Males
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D013420 Sulfamethoxazole A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208) Sulfamethylisoxazole,Gantanol,Sulfisomezole,Sulphamethoxazole
D014295 Trimethoprim A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported. Proloprim,Trimpex

Related Publications

S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
November 1973, The Journal of infectious diseases,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
January 1972, Chemotherapy,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
November 1973, The Journal of infectious diseases,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
July 2019, Clinical pharmacokinetics,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
January 1973, Therapie,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
June 1976, The Journal of antimicrobial chemotherapy,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
January 1974, Chemotherapy,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
December 1980, The New England journal of medicine,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
October 1987, Mayo Clinic proceedings,
S A Kaplan, and R E Weinfeld, and C W Abruzzo, and K McFaden, and M L Jack, and L Weissman
July 1999, Mayo Clinic proceedings,
Copied contents to your clipboard!